We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bausch plus Lomb Corporation | NYSE:BLCO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.31 | 2.11% | 15.02 | 15.15 | 14.59 | 14.75 | 259,816 | 01:00:00 |
Presentations Will Feature Blink® Triple Care Lubricating Dry Eye Drops, MIEBO™ (perfluorohexyloctane ophthalmic solution) and Bausch + Lomb INFUSE® Multifocal Lenses
Company Will Host Seven Educational Events
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one podium presentation and four poster presentations during the American Academy of Optometry (AAOpt) annual meeting, which will take place in New Orleans Oct. 11-14, 2023.
The podium presentation will highlight the results of a prospective, multi-center study that evaluated key clinical dry eye disease (DED) findings in patients using Blink Triple Care Dry Eye Lubricating Eye Drops. Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
Two poster presentations will include data on the newly launched MIEBO prescription eye drops, including an evaluation of the distribution and retention of MIEBO on the human eye and an analysis of the effect of MIEBO on fluorescein staining across all regions of the cornea. Additionally, two posters will feature data on Bausch + Lomb INFUSE Multifocal silicone hydrogel daily disposable contact lenses, which launched in June, including an evaluation of the lens’ clinical performance and an assessment of patient responses to the lens.
Bausch + Lomb will also host several educational events during the meeting featuring MIEBO eye drops, the new LUMIFY EYE ILLUMINATIONS™ product line, LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% and VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%. Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
The Bausch + Lomb schedule at AAOpt:
Podium Presentation
Poster Presentations
Featured Educational Events
Wednesday, October 11
Thursday, October 12
Friday, October 13
Important Safety Information for MIEBO
INDICATION
MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Click here for full Prescribing Information for MIEBO.
Important Safety Information for LOTEMAX SM
INDICATION
LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
IMPORTANT SAFETY INFORMATION
Click here for full Prescribing Information for LOTEMAX SM.
Important Safety Information for VYZULTA
INDICATION
VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
Please click here for full Prescribing Information.
Patients are encouraged to report negative side effects of these prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
© 2023 Bausch + Lomb.
MTB.0285.USA.23
View source version on businesswire.com: https://www.businesswire.com/news/home/20231004560490/en/
Media Contact: Kristy Marks kristy.marks@bausch.com (908) 927-0683
Investor Contact: George Gadkowski george.gadkowski@bausch.com (877) 354-3705 (toll free) (908) 927-0735
1 Year Bausch plus Lomb Chart |
1 Month Bausch plus Lomb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions